Abstract 5372
Background
Alzheimer’s disease showed different connections with various types of cancers and, even, both are protecting from each other. Some studies attributed it to shared genetic backgrounds. One of the shared mutations is located on APOE4 gene, a risk factor in Alzheimer’s, and was connected to chemotherapy-related deterioration of cognitive functions in breast cancer patients. Our aim is to examine the addon effect of radiation therapy on the risk of death from Alzheimer’s disease.
Methods
We collected data from 13 USA cancer registries enrolled in Surveillance Epidemiology and End Results program using SEER*stat software. We enrolled patients diagnosed with head and neck cancers or brain cancers between 1992 and 2016. The event was defined as death due to Alzheimer’s disease following the cancer diagnosis. Moreover, we have calculated Multiple Primary Standardized Incidence Ratios and excess risk per 10,000 person-years, to estimate the change of risk following the diagnosis when compared to the general population. Besides, we calculated the effect of gender, age, and receiving radiation for cancer.
Results
Out of 142,541 patients (59,630 patients with brain malignancies, and 82,911 with head and neck malignancies), 151 died due to Alzheimer’s after more than 10 years following a cancer diagnosis; 20 had brain malignancies, and 131 had other head and neck malignancies. The risk of Alzheimer’s death increased significantly after more than 10 years of a cancer diagnosis with an O/E ratio of 1.35 and an excess risk of 2.72 per 10,000. The risk increased significantly among females (81 females and O/E was 1.4) and males (70 and O/E was 1.29). Alzheimer’s was the cause of death in 52 patients who received Radiation therapy, and 13 patients who received chemotherapy with O/Es of 1.45 and 1.59 respectively. The risk of disease-related mortality was high in patients older than 70 years, while patients who were diagnosed with cancer earlier did not show a significant increase in their risk of Alzheimer’s death than the general population.
Conclusions
Risk of Alzehimer’s-related mortality increases significantly among survivors of head and neck cancers and brain cancers. Further studies shall address the biological risk-modifying effects of aging, gender, and treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract